Center for Molecular Biology of Oral Diseases, University of Illinois at Chicago, Chicago, IL 60637, USA.
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1256-65. doi: 10.1016/j.ijrobp.2010.06.029. Epub 2010 Oct 29.
To investigate the dosimetric feasibility of linear accelerator-based intensity-modulated total marrow irradiation (IM-TMI) in patients with hematologic malignancies.
Linear accelerator-based IM-TMI treatment planning was performed for 9 patients using the Eclipse treatment planning system. The planning target volume (PTV) consisted of all the bones in the body from the head to the mid-femur, except for the forearms and hands. Organs at risk (OAR) to be spared included the lungs, heart, liver, kidneys, brain, eyes, oral cavity, and bowel and were contoured by a physician on the axial computed tomography images. The three-isocenter technique previously developed by our group was used for treatment planning. We developed and used a common dose-volume objective method to reduce the planning time and planner subjectivity in the treatment planning process.
A 95% PTV coverage with the 99% of the prescribed dose of 12 Gy was achieved for all nine patients. The average dose reduction in OAR ranged from 19% for the lungs to 68% for the lenses. The common dose-volume objective method decreased the planning time by an average of 35% and reduced the inter- and intra- planner subjectivity.
The results from the present study suggest that the linear accelerator-based IM-TMI technique is clinically feasible. We have demonstrated that linear accelerator-based IM-TMI plans with good PTV coverage and improved OAR sparing can be obtained within a clinically reasonable time using the common dose-volume objective method proposed in the present study.
研究基于线性加速器的调强全骨髓照射(IM-TMI)在血液恶性肿瘤患者中的剂量学可行性。
使用 Eclipse 治疗计划系统为 9 例患者进行基于线性加速器的 IM-TMI 治疗计划。计划靶区(PTV)包括从头至股骨中部的全身骨骼,但不包括前臂和手部。需要保护的危险器官(OAR)包括肺、心脏、肝脏、肾脏、大脑、眼睛、口腔、肠道,并由医生在轴位 CT 图像上勾画。我们小组之前开发的三中心点技术用于治疗计划。我们开发并使用了一种通用的剂量-体积目标方法,以减少治疗计划过程中的规划时间和规划师的主观性。
所有 9 例患者的 PTV 覆盖率均达到 99%的处方剂量 12Gy,95%。OAR 的平均剂量降低幅度从肺的 19%到晶状体的 68%不等。通用剂量-体积目标方法平均减少了 35%的规划时间,并减少了内、外规划师的主观性。
本研究结果表明,基于线性加速器的 IM-TMI 技术在临床上是可行的。我们已经证明,使用本研究中提出的通用剂量-体积目标方法,可以在临床合理的时间内获得具有良好 PTV 覆盖率和改善 OAR 保护的基于线性加速器的 IM-TMI 计划。